Pfizer (NYSE:PFE) recently presented groundbreaking findings in cancer research, particularly the first-in-human Phase 1 clinical study of the innovative MesoC2 drug at the ASCO Annual Meeting, and ...

Jim Cramer once confidently backed Pfizer, praising its pipeline and high dividend, forecasting a big post-COVID comeback. “I ...

Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector. Markets expect ...

Pfizer, on the other hand, with its improving growth prospects, rising estimates, cheaper valuation, and higher dividend ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

This big drugmaker has been a favorite for income investors for years. However, its dividend is arguably more attractive than ever. At this writing, the forward dividend yield stands at a ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Evaluate AbbVie Inc. vs. Pfizer Inc. amidst tariff disputes and drug pricing policies. Click for our comparison of ABBV and ...

Of the 22 guru strategies we follow, PFE rates highest using our Shareholder Yield Investor model based on the published strategy of Meb Faber. This strategy looks for companies returning cash to ...

Trading for $23.03, PFE stock is down 13.5% year-to-date and 17% in 12 months. It has a dividend yield of 7.47%, which makes it worth an addition to your portfolio. It has increased dividends for ...

Kayne Anderson BDC , Inc. (NYSE:KBDC), with a market capitalization of $1.12 billion, has recently been the subject of analyst scrutiny, with its focus on middle-market direct lending and attractive ...

The company's next dividend payment will be US$0.43 per share, and in the last 12 months, the company paid a total of US$1.72 per share. Looking at the last 12 months of distributions, Pfizer has a ...